OSLO, NORWAY--(Marketwire - Jan 28, 2013) -
CD22 is a well-validated target for hematological cancers
Algeta ASA (OSE: ALGETA) has initiated a new
research program to evaluate a novel Targeted Thorium Conjugate (TTC)
combines Algeta's proprietary thorium-227 alpha-pharmaceutical payload
anti-CD22 monoclonal antibody (epratuzumab) developed by Immunomedics,
Epratuzumab is a humanised monoclonal antibody (mAb) that binds to the
glycoprotein on the surface of B cells. Epratuzumab has been evaluated
treatment of a variety of hematological cancers and for autoimmune diseases
as systemic lupus erythematosus (SLE).
Under the terms of this agreement, Immunomedics
will provide clinical-grade antibody to Algeta, which has rights to
evaluate the potential of a TTC, linking
thorium-227 to epratuzumab, for the treatment of cancer. Algeta will
preclinical and clinical development costs up to the end of phase I
Upon successful completion of phase I testing, the parties shall negotiate
for a license at Algeta's request according to certain parameters now
between the companies. Payments in the first year from Algeta to
include a signature fee, an antibody delivery milestone and payments for
antibody manufacture. No further details of the agreement are disclosed.
Thomas Ramdahl, Executive Vice President and Chief Technology Officer of
said: "The broad utility of our proprietary thorium-227 payload and
potential to be more effective at killing cancer cells than other
payloads gives Algeta a great opportunity to build an extensive
targeted cancer therapies. This collaboration brings together Algeta, the
leader in alpha-pharmaceuticals and Immunomedics, a pioneer in antibody
and technologies. A TTC based on a well-validated antibody such as
is an exciting prospect as we work to achieve our goal of generating a
candidate from the TTC platform in 2014".
Algeta's TTC strategy is based on gaining access to
carefully selected tumor-targeting molecules, via in-licensing,
collaboration or via third parties, to
which it links thorium-227 thereby creating potential new therapeutics.
disclosed TTC programs include collaborations with Sanofi and Ablynx,
based on HER2-targeting (breast/ovarian cancer)
and PDGFR-beta-targeting (anti-angiogenesis) molecules in-licensed from
Affibody and two programs targeting
hematological cancers, including this newly announced program.
About Algeta's TTC Platform
Algeta is evaluating the potential utility of alpha-particle emitting
in the treatment of cancer. Previous studies have indicated that such
elements may have value in treating cancers by causing double-strand DNA
that trigger cell death, and have also shown that the
effects of alpha-emission are highly localized as a result of the very
short range of the alpha particle
(2-10 cell diameters). Thorium-227 is one alpha-particle emitting element
(radionuclide) that has been selected by Algeta for further investigation.
linking thorium-227 to cancer-targeting molecules such as monoclonal
Algeta believes it may be possible to develop a pipeline
of targeted alpha-pharmaceuticals, termed Targeted Thorium Conjugates, or
TTCs. The TTC platform
is at an early research phase in development. Algeta intends to evaluate
a broad range of cancer types to determine whether the TTC platform could
advantages over naked (un-armed) antibodies or antibody-drug conjugate
technologies that use cytotoxic drugs (rather than alpha-emitting elements)
payloads. Such advantages may include increased potency, a more localized
tumoricidal effect and the potential to address drug resistance by virtue
physical action of the alpha particles.
For more information about Algeta's technology, please visit
Algeta is a company focused on developing novel targeted therapies for
with cancer based on its alpha-pharmaceutical platform. The
headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,
Cambridge, MA performing commercial marketing operations in the US.
listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information
This news release contains certain forward-looking statements that are
uncertainty, as they relate to events and depend on circumstances that
occur in the future and which, by their nature, may have an impact on
operations and the financial condition of Algeta.
Such forward-looking statements reflect our current views and are based
on the information currently
available to Algeta. Algeta cannot give any assurance as to whether such
looking statements will prove to be correct. These forward looking
include statements regarding future development activities generally and
program in particular. There are a number of factors that could cause
results and developments to differ materially from those expressed or
these forward-looking statements. These factors include, among other
risks or uncertainties associated with the success of future clinical
collaborations with other companies in the development of targeting
general economic and business conditions and difficulties of obtaining
governmental approvals for new products, and the other risks and
described in our annual report.
 Hall (1994) Radiobiology for the Radiologist (Lippincott, Philadelphia)
This information is subject of the disclosure requirements pursuant to
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE